OurInsightsTitle

Our extensive experience in health technology
assessment (HTA) through providing strategic
advice and guiding evidence generation to
support submissions to UK HTA bodies, enables
us to provide you with a tailored solution to
reimbursement and patient access.

The 2023 EB Insights Study: the impact of epidermolysis bullosa on the health related quality of life of patients and their carers. Poster PCR97. Presented at: ISPOR Europe 2024; 17-20 November 2024; Barcelona, Spain.

Register to access the Tolley insights